This Drug Could Help Millions Battling Obesity

The obesity epidemic in the U.S. is only getting worse.

In fact, by the time 2030 rolls around, nearly half of all U.S. adults are projected to be obese, according to Harvard researchers, as noted by MSN.  While some companies have suggested using “magnets cemented to your teeth to stop you opening your mouth by more than a couple of millimeters,” as reported by The Guardian, other companies believe the use of psilocybin could be far more beneficial.  That could be great news for companies such as NeonMind Biosciences (CSE:NEON)(OTC:NMDBF), ATAI Life Sciences (NASDAQ:ATAI), Mind Medicine (NASDAQ:MNMD)(NEO:MNMD), Cresco Pharma Ltd. (OTC:COPHF), and Pharmather Holdings Ltd. (CSE:PHRM)(OTC:PHRRF).

NeonMind Biosciences, for example, has two drug development candidates exploring psilocybin as an innovative treatment approach to treat obesity and support weight loss. NeonMind’s first drug candidate employs psilocybin as an agonist to the serotonin receptor 5-HT2A, which is involved in the hallucinogenic effect of psychedelics, and the second drug candidate employs psilocybin as an agonist to the serotonin 5-HT2C receptor, which controls appetite.